Phase I Study in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Patients to Determine the Recommended Dose of the Investigational Product (CYAD-02)

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome Interventions:   Biological: CYAD-02;   Drug: ENDOXAN;   Drug: Fludara Sponsor:   Celyad (formerly named Cardio3 BioSciences) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials